

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE

03 AUG 14 PM 12:51

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Aventis Pharmaceuticals (formerly known as Aventis Pharmaceuticals Inc.)			
2. Address <input type="checkbox"/> Check if different than previously reported 801 Pennsylvania Avenue, NW, Suite 725			
3. Principal Place of Business (if different from line 2) Washington DC 20004 City: State/zip (or Country)			
4. Contact Name Ann Taylor	Telephone (202) 898-3183	E-mail (optional) Ann.Taylor@aventis.com	5. Senate ID # 56838-12
7. Client Name <input checked="" type="checkbox"/> Self self			6. House ID # 35186000

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December)
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇨ Termination Date _____11. No Lobbying **INCOME OR EXPENSES** Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇨ \$ _____ <small>Income (nearest \$20,000)</small>	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>\$1,300,000.00</u> <small>Expenses (nearest \$20,000)</small>
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate exp accounting method. See instructions for description of opt <input type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6033(f) Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature _____ Date _____

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Discussions with the Environmental Protection Agency (EPA) to continue distribution of aerosol medication for patients suffering from allergic rhinitis and related conditions until FDA approval of a non-CFC alternative product.

17. House(s) of Congress and Federal agencies contacted Check if None

Environmental Protection Agency

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals part of Aventis SA. Aventis Pharmaceuticals had an interest in obtaining an exception from EPA to avoid disruption of aerc products to patients.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Discussions with the Centers for Medicaid and Medicare Services (CMS) on reimbursement policy in Medicare Part B.

17. House(s) of Congress and Federal agencies contacted Check if None

Centers for Medicaid and Medicare Services, Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Eddie Evans	
Ann Taylor	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis-Pharmaco part of Aventis SA. Aventis Pharmaceuticals interest in this issue is to ensure that essential pharmaceutical benefit cover available to the Medicare population.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Switch of prescription drugs to over-the-counter.

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Eddie Evans	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals' interest in this issue is to ensure that public policy supports continued development of new and better pharmaceuticals that are needed by patients.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and providing information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

S. 1225 "Greater Access to Affordable Pharmaceutical Act"
All provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Eddie Evans	
Ann Taylor	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is a part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that the legislation supports continued development of new and better pharmaceuticals needed by patients.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each co information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 1113 "Improved Access to Osteoporosis Testing Act of 2003"
All provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Ann Taylor	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmac part of Aventis SA. Aventis Pharmaceuticals is interested in this bill to ensure th beneficiaries will have access to bone mineral screening for osteoporosis.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R. 908 "Access to Innovations for Medicare Patients Act of 2003"
 S. 465 "Access to Innovations for Medicare Patients Act of 2003"

 All Provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
 U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ann Taylor	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is a part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that essential pharmaceutical benefit coverage is available to the Medicare population.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R. 2469 "Medicare Reform Act of 2003"
 H.R. 1 "Medicare Drug Benefit and Modernization Act of 2003"
 S. 1 "Medicare Drug Benefit and Improvement Act of 2003"

 All provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
 U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Eddie Evans	
Ann Taylor	
Richard Hodge	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmacia part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that essential pharmaceutical benefit coverage is available to the Medicare population.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each co information as requested. Attach additional page(s) as needed.

15. General issue area code TOR (one per page)

16. Specific lobbying issues

H.R. 1115 "Class Action Fairness Act of 2003"
All provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaco part of Aventis SA. Aventis Pharmaceuticals is interested in this legislation so th interstate class action suits could be heard in federal court.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

H.R. 2673 "Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2004"
 All provisions relating to reimportation.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Eddie Evans	
Judy Cook	
Ann Taylor	
Richard Hodge	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is a part of Aventis SA. Aventis Pharmaceuticals is interested in this bill to ensure that the safety of U.S. pharmaceuticals is preserved for all Americans.

Signature _____ Date _____

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Registrant Name Aventis Pharmaceuticals Client Name self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 2427 "Pharmaceutical Market Access Act of 2003"
All provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Richard Hodge	
Ann Taylor	
Eddie Evans	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is a part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that the U.S. pharmaceutical industry is not subjected to unfair price restraints and American public is not subjected to unsafe pharmaceuticals.

Signature  Date 8-14-03

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

